Compare · CBUS vs NXTS
CBUS vs NXTS
Side-by-side comparison of Cibus Inc. (CBUS) and Nexentis Technologies Inc. (NXTS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CBUS and NXTS operate in Agricultural Chemicals (Industrials), so they compete in similar markets.
- CBUS is the larger of the two at $123.1M, about 50.7x NXTS ($2.4M).
- Over the past year, CBUS is up 15.7% and NXTS is down 96.8% - CBUS leads by 112.5 points.
- NXTS has hit the wire 1 time in the past 4 weeks while CBUS has been quiet.
- CBUS has more recent analyst coverage (4 ratings vs 0 for NXTS).
PerformanceCBUS+16.91%NXTS-96.83%
2025-09-10+0.00%2026-09-09
- Company
- Cibus Inc.
- Nexentis Technologies Inc.
- Price
- $1.63+0.62%
- $1.73-2.26%
- Market cap
- $123.1M
- $2.4M
- 1M return
- -14.47%
- -8.47%
- 1Y return
- +15.66%
- -96.83%
- Industry
- Agricultural Chemicals
- Agricultural Chemicals
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2017
- News (4w)
- 0
- 1
- Recent ratings
- 4
- 0
Latest CBUS
- SEC Form 10-Q filed by Cibus Inc.
- Cibus Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Cibus Reports Second Quarter Financial Results and Provides Business Update
- Cibus to Report Second Quarter 2026 Financial Results on August 13, 2026 After the Market Close and Host Conference Call
- SEC Form S-8 filed by Cibus Inc.
- SEC Form S-8 filed by Cibus Inc.
- Europe Recognizes Nature-Based Plant Improvement, Opening a New Pathway for Cibus
- CEO Wichner Craig was granted 894,309 shares (SEC Form 4)
- Cibus Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- Cibus Names Agricultural Biotechnology Leader Craig Wichner as Chief Executive Officer to Accelerate Growth and Value Creation
Latest NXTS
- Nexentis Technologies Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
- SEC Form 10-Q filed by Nexentis Technologies Inc.
- Nexentis Technologies Inc. filed SEC Form 8-K: Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits
- Nexentis Technologies Subsidiary MitoCareX Bio Selects Transport Protein Candidate for Drug Discovery Campaign
- SEC Form EFFECT filed by Nexentis Technologies Inc.
- SEC Form EFFECT filed by Nexentis Technologies Inc.
- SEC Form S-1 filed by Nexentis Technologies Inc.
- SEC Form POS AM filed by Nexentis Technologies Inc.
- Nexentis Subsidiary MitoCareX Bio Advances SLC Transporter Drug Discovery with Broad Analysis and International AI Initiative
- Nexentis Announces Monetization of Part of its Melz Solar Investment at $14.5 Million Project Valuation – Significant Premium to Initial Investment